BofA raises Novavax stock target from USD 7.00 to USD 8.00

Published on 10/15/2026 at 20:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue fell 76.20 percent to USD 56.70 million. Novavax stock costs EUR 11.53 on October 15, 2026.

Analyst target and upcoming results

BofA moved its Novavax target from USD 7.00 to USD 8.00 on October 9, 2026.
Second-quarter 2026 revenue was USD 56.70 million, down 76.20 percent year over year.
Novavax stock costs EUR 11.53 at Lang & Schwarz on October 15, 2026 at 8:08 p.m. CEST.
Novavax is estimated to report third-quarter results on November 5, 2026.

NVAX, US6700024010, Illustration mit AI erstellt.

Bank of America raised its Novavax target from USD 7.00 to USD 8.00 on October 9, 2026, but kept an Underperform rating. As Markets Insider reported, the target was set in a third-quarter earnings preview. The target is 37.89 percent below the USD 12.88 Nasdaq price quoted on October 15, 2026.

At 8:08 p.m. CEST on October 15, 2026, Novavax stock was trading at EUR 11.53 at Lang & Schwarz.

Revenue reset shapes the picture

Novavax reported USD 56.70 million in revenue for the second quarter of 2026, down 76.20 percent from USD 239.00 million in the second quarter of 2025. The comparison is heavily affected by a USD 202.00 million prior-year benefit from a BLA approval milestone and a Takeda amendment, according to Benzinga.

The company recorded a USD 53.39 million net loss and diluted earnings per share of negative USD 0.32 in the same quarter. Product sales reached USD 19.00 million, while partner-related revenue included USD 36.00 million from Sanofi-related activities.

Price position and valuation

The Nasdaq quote stood at USD 12.88 on October 15, 2026 at 2:14 p.m. ET, with a session range of USD 6.20 to USD 13.39 over the past 52 weeks. The USD 12.88 price was 3.81 percent below the yearly high. Trading volume was 4,788,779 shares against an average of 5,668,376 shares.

Novavax had a market capitalization of USD 2.1 billion and a price-to-earnings ratio of negative 8.46 as of October 15, 2026. MarketBeat estimates that the company will report third-quarter 2026 results on November 5, 2026, before the market opens, with the call scheduled for 8:30 a.m. ET.

Comparison with peers

NVAX (Nasdaq, USD): price-to-earnings ratio -8.46, market capitalization USD 2.1 billion.

Moderna (Nasdaq, USD): daily change plus 5.22 percent, price-to-earnings ratio -29.87, market capitalization USD 95.1 billion.

BioNTech (Nasdaq, USD): daily change plus 1.81 percent, price-to-earnings ratio -11.79, market capitalization USD 22.6 billion.

What comes next for Novavax

The November reporting date gives investors the next fixed checkpoint for judging whether the partnership-led model can offset weaker quarterly revenue. The combination of a negative price-to-earnings ratio, a USD 53.39 million quarterly loss and a target below the Nasdaq quote keeps the valuation discussion tied to execution rather than a simple growth multiple.

The further course of trading is shown by the continuously updated real-time quote of Novavax stock.